Novartis announced that after conducting an interim analysis from the CIRRUS-1 trial of CFZ533 (iscalimab), the company is discontinuing the study in kidney transplant patients.

J&J’s Janssen Pharmaceutical released new long-term data from the open-label period of the Phase III VOYAGE 1 study.

Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.